Merck & Co., Inc. MRK
NYSE · XNYS · stock
Chart by TradingView
4/9
Piotroski F — financial health
—
Altman Z″ — distress risk
44.8%
Dividend payout · moderate
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $65.0B | $18.3B | — | $12.4B | $52.7B |
| 2024 | $64.2B | $17.1B | — | $18.1B | $46.4B |
| 2023 | $60.1B | $365.0M | — | $9.1B | $37.6B |
| 2022 | $59.3B | $14.5B | — | $14.7B | $46.1B |
| 2021 | $48.7B | $13.0B | — | $8.7B | $38.3B |
| 2020 | $41.5B | $7.1B | — | — | $25.4B |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Source: SEC EDGAR filings · CIK 0000310158 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.